share_log

Sterling Check Analyst Ratings

Benzinga ·  Nov 9, 2023 09:43
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/09/2023 24.44% Morgan Stanley $15 → $14 Maintains Equal-Weight
09/05/2023 42.22% Goldman Sachs $14 → $16 Maintains Buy
07/13/2023 24.44% Goldman Sachs $16 → $14 Maintains Buy
05/10/2023 33.33% Morgan Stanley $16 → $15 Maintains Equal-Weight
04/13/2023 42.22% Goldman Sachs $18 → $16 Maintains Buy
04/12/2023 42.22% Goldman Sachs $18 → $16 Maintains Buy
03/03/2023 60% Goldman Sachs $20 → $18 Maintains Buy
03/03/2023 42.22% Morgan Stanley $17 → $16 Maintains Equal-Weight
02/10/2023 Needham Downgrades Buy → Hold
01/25/2023 Keybanc Downgrades Overweight → Sector Weight
01/19/2023 77.78% Goldman Sachs $18 → $20 Maintains Buy
11/10/2022 60% Goldman Sachs $21 → $18 Maintains Buy
11/10/2022 51.11% Morgan Stanley $23 → $17 Maintains Equal-Weight
11/10/2022 60% Baird $28 → $18 Maintains Outperform
11/10/2022 42.22% Keybanc $29 → $16 Maintains Overweight
11/10/2022 77.78% Needham $27 → $20 Maintains Buy
11/08/2022 86.67% Goldman Sachs $24 → $21 Maintains Buy
09/27/2022 104.44% Morgan Stanley $25 → $23 Maintains Equal-Weight
09/21/2022 140% Needham → $27 Initiates Coverage On → Buy
08/10/2022 122.22% Morgan Stanley $24 → $25 Maintains Equal-Weight
07/20/2022 113.33% Morgan Stanley $26 → $24 Maintains Equal-Weight
05/16/2022 60% Barclays $22 → $18 Maintains Equal-Weight
05/11/2022 157.78% Goldman Sachs $33 → $29 Maintains Buy
04/11/2022 131.11% Morgan Stanley → $26 Downgrades Overweight → Equal-Weight
04/01/2022 157.78% Keybanc $25 → $29 Maintains Overweight
03/16/2022 95.56% Barclays $28 → $22 Maintains Equal-Weight
03/03/2022 131.11% Morgan Stanley $25 → $26 Maintains Overweight
03/03/2022 122.22% Keybanc $31 → $25 Maintains Overweight
01/05/2022 122.22% Morgan Stanley $28 → $25 Upgrades Equal-Weight → Overweight
11/23/2021 148.89% Barclays → $28 Initiates Coverage On → Equal-Weight
11/11/2021 175.56% Keybanc $30 → $31 Maintains Overweight
10/18/2021 148.89% Morgan Stanley → $28 Initiates Coverage On → Equal-Weight
10/18/2021 William Blair Initiates Coverage On → Outperform
10/18/2021 157.78% Wolfe Research → $29 Initiates Coverage On → Peer Perform
10/18/2021 202.22% Baird → $34 Initiates Coverage On → Outperform
10/18/2021 166.67% Stifel → $30 Initiates Coverage On → Buy
10/18/2021 166.67% JP Morgan → $30 Initiates Coverage On → Overweight
10/18/2021 228.89% Goldman Sachs → $37 Initiates Coverage On → Buy
10/18/2021 166.67% Keybanc → $30 Initiates Coverage On → Overweight

What is the target price for Sterling Check (STER)?

The latest price target for Sterling Check (NASDAQ: STER) was reported by Morgan Stanley on November 9, 2023. The analyst firm set a price target for $14.00 expecting STER to rise to within 12 months (a possible 24.44% upside). 16 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Sterling Check (STER)?

The latest analyst rating for Sterling Check (NASDAQ: STER) was provided by Morgan Stanley, and Sterling Check maintained their equal-weight rating.

When is the next analyst rating going to be posted or updated for Sterling Check (STER)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sterling Check, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sterling Check was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.

Is the Analyst Rating Sterling Check (STER) correct?

While ratings are subjective and will change, the latest Sterling Check (STER) rating was a maintained with a price target of $15.00 to $14.00. The current price Sterling Check (STER) is trading at is $11.25, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment